Lexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Free Report) in a research report report published on Monday morning. The firm issued a sell rating on the biopharmaceutical company's stock.

Several other research firms also recently commented on LXRX. Needham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Piper Sandler lowered their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Leerink Partners reiterated a "market perform" rating and set a $1.00 target price (down from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Friday, March 28th. Finally, Leerink Partnrs cut Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $3.67.

Lexicon Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ LXRX traded up $0.01 during trading on Monday, reaching $0.71. The company had a trading volume of 4,496,053 shares, compared to its average volume of 6,429,083. Lexicon Pharmaceuticals has a 12-month low of $0.28 and a 12-month high of $2.45. The business's 50-day moving average is $0.49 and its 200 day moving average is $0.85. The stock has a market cap of $174.58 million, a PE ratio of -0.95 and a beta of 1.02. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. The firm had revenue of $26.55 million for the quarter, compared to analysts' expectations of $6.48 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. As a group, equities analysts forecast that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Bayesian Capital Management LP purchased a new position in Lexicon Pharmaceuticals during the fourth quarter valued at approximately $31,000. RPO LLC purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter worth $33,000. Renaissance Technologies LLC bought a new stake in Lexicon Pharmaceuticals during the fourth quarter valued at about $38,000. Arizona State Retirement System lifted its position in shares of Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 16,136 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its position in shares of Lexicon Pharmaceuticals by 60.3% during the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock worth $48,000 after purchasing an additional 24,615 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.